Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 5/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MST1R | Q04912 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMP4 | P12644 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240526 | 0.82 | IKBKE (0.40) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4060549 | 0.76 | MAPK9 (0.46) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4061377 | 0.76 | CYP11B1 (0.44) | IDO1RETMETLTKGRK5 | |
| SCHEMBL4071816 | 0.74 | BRD4 (0.45) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4065718 | 0.73 | LTK (0.55) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4241887 | 0.73 | LTK (0.41) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4239547 | 0.72 | LTK (0.40) | RETMETLTKGRK5CDK8 | |
| SCHEMBL4504820 | 0.72 | PDE5A (0.48) | RETMETLTKGRK5CDK8 | |
| SCHEMBL22015704 | 0.72 | CYP3A4 (0.62) | ACVR1IDO1BMP4GSK3BCYP1A2 | |
| SCHEMBL18229915 | 0.71 | PDE3B (0.49) | RETMETLTKGRK5CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | claimed |
| EP-2013212-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | claimed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2013212-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254879-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | ACVR1 1831/4885IDO1 1125/4885RET 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.